Publications

Anderson, K. M., Zhao, Y., Xiao, N., Ge, J., & Weisman, H. F. (2024). Some group sequential trials from industry over the last 30 years. Statistics in Biopharmaceutical Research, 16(3), 281–293. https://doi.org/10.1080/19466315.2024.2334354

León, L. F., Jemielita, T., Guo, Z., West, R. M., & Anderson, K. M. (2024). Exploratory subgroup identification in the heterogeneous Cox model: A relatively simple procedure. Statistics in Medicine. https://doi.org/10.1002/sim.10163

Zhang, H., Anderson, K. M., Zimmer, Z., Golm, G., Sapre, A., & Ibrahim, J. G. (2024). Prior effective sample size when borrowing on the treatment effect scale. arXiv Preprint arXiv:2404.13366. https://doi.org/10.48550/arXiv.2404.13366

Anderson, K. M., Wan, S., & Zhang, H. (2023). Practical considerations for adaptive design. Biopharmaceutical Report, 30(2), 11–15. https://community.amstat.org/biop/biopharmreport

Li, Y., Zhang, H., Anderson, K., Li, S., & Zhu, R. (2023). AI in pharma for personalized sequential decision-making: Methods, applications and opportunities. arXiv Preprint arXiv:2311.18725. https://doi.org/10.48550/arXiv.2311.18725

Lin, R. S., Mukhopadhyay, P., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Lin, J., Liu, R., Luo, X., Mai, Y., Qin, R., Tatsuoka, K., Wang, Y., Ye, J., Zhu, J., Chen, T.-T., Iacona, R., & Cross-Pharma Non-proportional Hazards Working Group. (2023). Comment on “Non-proportional hazards–an evaluation of the MaxCombo test in cancer clinical trials” by the cross-pharma non-proportional hazards working group. Statistics in Biopharmaceutical Research, 15(2), 312–314. https://doi.org/10.1080/19466315.2022.2103180

Miao, G., Liao, J. J., Yang, J., & Anderson, K. (2023). A gated group sequential design for seamless phase II/III trial with subpopulation selection. BMC Medical Research Methodology, 23(2). https://doi.org/10.1186/s12874-022-01825-0

Mukhopadhyay, P., Roychoudhury, S., & Anderson, K. M. (2023). The MaxCombo test severely violates the type I error rate—reply. JAMA Oncology, 9(4), 572. https://doi.org/10.1001/jamaoncol.2022.7750

Roychoudhury, S., Anderson, K. M., Ye, J., & Mukhopadhyay, P. (2023). Robust design and analysis of clinical trials with nonproportional hazards: A straw man guidance from a cross-pharma working group. Statistics in Biopharmaceutical Research, 15(2), 280–294. https://doi.org/10.1080/19466315.2021.1874507

Zhao, Y., Liu, Q., Sun, L. Z., & Anderson, K. M. (2023). Adjusted inference for multiple testing procedure in group sequential designs. arXiv Preprint arXiv:2311.15498. https://doi.org/10.48550/arXiv.2311.15498

Zhao, Y., Xiao, N., Anderson, K., & Zhang, Y. (2023). Electronic common technical document submission with analysis using R. Clinical Trials, 20(1), 89–92. https://doi.org/10.1177/17407745221123244

Zhao, Y., Zhang, Y., Leon, L., & Anderson, K. M. (2023). Group sequential design under non-proportional hazards. arXiv Preprint arXiv:2312.01723. https://doi.org/10.48550/arXiv.2312.01723

Anderson, K. M., Guo, Z., Zhao, J., & Sun, L. Z. (2022). A unified framework for weighted parametric group sequential design. Biometrical Journal, 64(7), 1219–1239. https://doi.org/10.1002/bimj.202100085

Mukhopadhyay, P., Ye, J., Anderson, K. M., Roychoudhury, S., Rubin, E. H., Halabi, S., & Chappell, R. J. (2022). Log-rank test vs MaxCombo and difference in restricted mean survival time tests for comparing survival under nonproportional hazards in immuno-oncology trials: A systematic review and meta-analysis. JAMA Oncology, 8(9), 1294–1300. https://doi.org/10.1001/jamaoncol.2022.2666

Bautista, O., & Anderson, K. (2021). Sample size estimation and power analysis: Time to event data. In Handbook of statistical methods for randomized controlled trials (pp. 275–300). Chapman; Hall/CRC. https://doi.org/10.1201/9781315119694

Chen, T.-Y., Zhao, J., Sun, L., & Anderson, K. M. (2021). Multiplicity for a group sequential trial with biomarker subpopulations. Contemporary Clinical Trials, 101, 106249. https://doi.org/10.1016/j.cct.2020.106249

León, L. F., Lin, R., & Anderson, K. M. (2020). On weighted log-rank combination tests and companion Cox model estimators. Statistics in Biosciences, 12(2), 225–245. https://doi.org/10.1007/s12561-020-09276-1

Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis. Statistics in Biopharmaceutical Research, 12(2), 187–198. https://doi.org/10.1080/19466315.2019.1697738

Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020). Rejoinder to letter to the editor “the hazards of period specific and weighted hazard ratios”. Statistics in Biopharmaceutical Research, 12(4), 520. https://doi.org/10.1080/19466315.2020.1825522

Tian, L., Jin, H., Uno, H., Lu, Y., Huang, B., Anderson, K. M., & Wei, L. (2020). On the empirical choice of the time window for restricted mean survival time. Biometrics, 76(4), 1157–1166. https://doi.org/10.1111/biom.13237

Wang, S., Ye, S., Anderson, K. M., & Zhang, Y. (2020). r2rtf—an R package to produce Rich Text Format (RTF) tables and figures. PharmaSUG. https://www.pharmasug.org/proceedings/2020/DV/PharmaSUG-2020-DV-198.pdf

Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): A randomised, placebo-controlled trial. The Lancet, 392(10161), 2269–2279. https://doi.org/10.1016/S0140-6736(18)32328-6

Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., & Tse, A. (2018). A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development. Contemporary Clinical Trials, 64, 238–242. https://doi.org/10.1016/j.cct.2017.09.006

Chen, C., Anderson, K., Mehrotra, D. V., Rubin, E. H., & Tse, A. (2018). Designing clinical trials in tumor indications with a positive signal in phase 1. Cancer Research, 78(13_Supplement), 4759–4759. https://doi.org/10.1158/1538-7445.AM2018-4759

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., et al. (2018). Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with Pembrolizumab. Clinical Cancer Research, 24(20), 4960–4967. https://doi.org/10.1158/1078-0432.CCR-17-2386

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W.-J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., et al. (2018). Correction: Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with Pembrolizumab. Clinical Cancer Research, 24(23), 6098–6098. https://doi.org/10.1158/1078-0432.CCR-18-3340

Turner, D. C., Kondic, A. G., Anderson, K. M., Robinson, A. G., Garon, E. B., Riess, J. W., Jain, L., Mayawala, K., Kang, J., Ebbinghaus, S. W., et al. (2018). Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clinical Cancer Research, 24(23), 5841–5849. https://doi.org/10.1158/1078-0432.CCR-18-0415

Ivanova, A., Anderson, K. M., Rosner, G. L., & Rubin, E. (2015). Comment. Statistics in Biopharmaceutical Research, 7(4), 357–358. https://doi.org/10.1080/19466315.2015.1094407

Wan, H., Ellenberg, S. S., & Anderson, K. M. (2015). Stepwise two-stage sample size adaptation. Statistics in Medicine, 34(1), 27–38. https://doi.org/10.1002/sim.6311

Anderson, K. M. (2014). Group sequential design in R. In Clinical trial biostatistics and biopharmaceutical applications (pp. 179–209). CRC Press New York. https://doi.org/10.1201/b17716

Anderson, K. M. (2014). Timing and frequency of interim analyses in confirmatory trials. In Practical considerations for adaptive trial design and implementation (pp. 115–123). Springer. https://doi.org/10.1007/978-1-4939-1100-4_6

Anderson, K., Joffe, M., & Kosorok, M. R. (2014). University of Pennsylvania 6th annual conference on statistical issues in clinical trials: Dynamic treatment regimes (morning session). Clinical Trials, 11(4), 418–425. https://doi.org/10.1177/1740774514538553

He, W., Pinheiro, J., & Kuznetsova, O. M. (2014). Practical considerations for adaptive trial design and implementation. Springer. https://doi.org/10.1007/978-1-4939-1100-4

Herzog, T., Anderson, K., Wang, J., & Xu, R. (2014). Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor-positive target. Gynecologic Oncology, 133, 178–179. https://doi.org/10.1016/j.ygyno.2014.03.470

Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Hwu, W.-J., Kefford, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P., Perrone, A. M., Kang, S. P., Ebbinghaus, S., Anderson, K. M., & Gangadhar, T. C. (2014). Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology, 32(15_suppl), 3015–3015. https://doi.org/10.1200/jco.2014.32.15_suppl.3015

Naumann, R., Bidzinski, M., Lovejoy, C., Anderson, K., Rangwala, R., & Kutarska, E. (2014). CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: The PRECEDENT trial. Gynecologic Oncology, 133, 177–178. https://doi.org/10.1016/j.ygyno.2014.03.468

Zhou, J., Adewale, A., Shentu, Y., Liu, J., & Anderson, K. (2014). Information-based sample size re-estimation in group sequential design for longitudinal trials. Statistics in Medicine, 33(22), 3801–3814. https://doi.org/10.1002/sim.6192

Anderson, K. M., Chan, I. S., & Li, X. (2012). An adaptive design for case-driven vaccine efficacy study when incidence rate is unknown. Statistics and Its Interface, 5(4), 391–399. https://doi.org/10.4310/SII.2012.v5.n4.a2

He, W., Kuznetsova, O. M., Harmer, M., Leahy, C., Anderson, K., Dossin, N., Li, L., Bolognese, J., Tymofyeyev, Y., & Schindler, J. (2012). Practical considerations and strategies for executing adaptive clinical trials. Drug Information Journal: DIJ/Drug Information Association, 46(2), 160–174. https://doi.org/10.1177/0092861512436580

Liu, Q., Li, G., Anderson, K. M., & Lim, P. (2012). On efficient two-stage adaptive designs for clinical trials with sample size adjustment. Journal of Biopharmaceutical Statistics, 22(4), 617–640. https://doi.org/10.1080/10543406.2012.678226

Anderson, K. M., & Clark, J. B. (2010). Fitting spending functions. Statistics in Medicine, 29(3), 321–327. https://doi.org/10.1002/sim.3737

Anderson, K. M., & Clark, J. (2010). Group sequential design: Selecting appropriate bounds. Journal of Clinical Oncology, 28(15_suppl), e13159–e13159. https://doi.org/10.1200/jco.2010.28.15\suppl.e13159

Chen, Y. J., & Anderson, K. M. (2010). A “MiniPool” approach for combined phase IIB/III trial in patients with life-threatening disease: An application of the closed testing principle. Statistics in Biopharmaceutical Research, 2(1), 62–71. https://doi.org/10.1198/sbr.2009.0038

Ellenberg, S., Ruberg, S., Simon, R., Wang, S.-J., Xu, L.-A., & Anderson, K. (2010). Closing discussion. Clinical Trials, 7(5), 611–616. https://doi.org/10.1177/1740774510380503

Gallo, P., Anderson, K., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2010). Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group. Journal of Biopharmaceutical Statistics, 20(6), 1115–1124. https://doi.org/10.1080/10543406.2010.514452

Rubin, E. H., & Anderson, K. M. (2010). Finding the right dose for cancer therapeutics—can we do better? Clinical Cancer Research, 16(4), 1085–1087. https://doi.org/10.1158/1078-0432.CCR-09-3246

Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein, C., Dudinak, J., Fardipour, P., Gallo, P., Givens, S., Lewis, R., et al. (2009). Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal, 43(5), 539–556. https://doi.org/10.1177/009286150904300503

Lupinacci, L., Anderson, K., Sun, L., & Tymofyeyev, Y. (2009). Novel phase i design for oncology research. Journal of Clinical Oncology, 27(15_suppl), 2517–2517. https://doi.org/10.1200/jco.2009.27.15\suppl.2517

Liu, Q., & Anderson, K. M. (2008). On adaptive extensions of group sequential trials for clinical investigations. Journal of the American Statistical Association, 103(484), 1621–1630. https://doi.org/10.1198/016214508000000986

Liu, Q., & Anderson, K. (2008). Theory of inference for adaptively extended group sequential designs with applications in clinical trials. Journal of the American Statistical Association, Supplemental Archive. https://www.tandfonline.com/doi/suppl/10.1198/016214508000000986

Anderson, K. M. (2007). Optimal spending functions for asymmetric group sequential designs. Biometrical Journal: Journal of Mathematical Methods in Biosciences, 49(3), 337–345. https://doi.org/10.1002/bimj.200510205

Cohen, Y. C., Liu, K. S., Heyden, N. L., Carides, A. D., Anderson, K. M., Daifotis, A. G., & Gann, P. H. (2007). Detection bias due to the effect of finasteride on prostate volume: A modeling approach for analysis of the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 99(18), 1366–1374. https://doi.org/10.1093/jnci/djm130

Chuang-Stein, C., Anderson, K., Gallo, P., & Collins, S. (2006). Sample size reestimation: A review and recommendations. Drug Information Journal: DIJ/Drug Information Association, 40(4), 475–484. https://doi.org/10.1177/216847900604000413

Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006). Adaptive designs in clinical drug development—an executive summary of the PhRMA working group. Journal of Biopharmaceutical Statistics, 16(3), 275–283. https://doi.org/10.1080/10543400600614742

Antman, E. M., Cooper, H., Gibson, C., Lemos, J. A. de, McCabe, C., Giugliano, R., Coussement, P., Murphy, S., Scherer, J., Anderson, K., et al. (2002). Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction. Insights from TIMI 14 and InTIME-II. European Heart Journal, 23(12), 928–933. https://doi.org/10.1053/euhj.2001.2964

Kereiakes, D. J., Lincoff, A. M., Anderson, K. M., Achenbach, R., Patel, K., Barnathan, E., Califf, R. M., & Topol, E. J. (2002). Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. American Journal of Cardiology, 90(6), 628–630. https://doi.org/10.1016/s0002-9149(02)02568-7

Akkerhuis, K. M., Deckers, J. W., Lincoff, A. M., Tcheng, J. E., Boersma, E., Anderson, K., Balog, C., Califf, R. M., Topol, E. J., & Simoons, M. L. (2001). Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA, 286(1), 78–82. https://doi.org/10.1001/jama.286.1.78

Anderson, K. M., Califf, R. M., Stone, G. W., Neumann, F.-J., Montalescot, G., Miller, D. P., Ferguson, J. J., Willerson, J. T., Weisman, H. F., & Topol, E. J. (2001). Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology, 37(8), 2059–2065. https://doi.org/10.1016/s0735-1097(01)01290-6

Kereiakes, D., Anderson, K., Achenbach, R., Melsheimer, R., Kurz, M., & Barnathan, E. (2001). Abciximab survival advantage is not explained by reduction in early major cardiac events: EPIC, EPILOG and EPISTENT 3 year analysis. Circulation, 104, 87–88.

Antman, E. M., Gibson, C., Lemos, J. A. de, Giugliano, R., McCabe, C., Coussement, P., Menown, I., Nienaber, C., Rehders, T., Frey, M., et al. (2000). Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14. European Heart Journal, 21(23), 1944–1953. https://doi.org/10.1053/euhj.2000.2243

Lemos, J. A. de, Antman, E. M., Gibson, C. M., McCabe, C. H., Giugliano, R. P., Murphy, S. A., Coulter, S. A., Anderson, K., Scherer, J., Frey, M. J., et al. (2000). Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation, 101(3), 239–243. https://doi.org/10.1161/01.cir.101.3.239

The Abciximab in Ischemic Stroke Investigators. (2000). Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke, 31(3), 601–609. https://doi.org/10.1161/01.str.31.3.601

Kereiakes, D. J., Berkowitz, S. D., Lincoff, A. M., Tcheng, J. E., Wolski, K., Achenbach, R., Melsheimer, R., Anderson, K., Califf, R. M., & Topol, E. J. (2000). Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. American Heart Journal, 140(1), 74–80. https://doi.org/10.1067/mhj.2000.106615

Kereiakes, D., Lincoff, A., Achenbach, R., Melsheimer, R., Kurz, M., Califf, R., Anderson, K., & Topol, E. (2000). Long-term abciximab survival advantage is not explained by reduction in early major cardiac events. American Journal of Cardiology, 86, 13I–13I.

Lincoff, A. M., Mark, D. B., Tcheng, J. E., Califf, R. M., Bala, M. V., Anderson, K. M., Davidson-Ray, L., Knight, J. D., Cabot, C. F., & Topol, E. J. (2000). Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: Results from the EPILOG randomized trial. Circulation, 102(24), 2923–2929. https://doi.org/10.1161/01.cir.102.24.2923

Anderson, K., Cabot, C., & Tcheng, J. (1999). Abciximab reduces in-hospital events among patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 84, 67P–67P.

Anderson, K. M., Bala, M. V., & Weisman, H. F. (1999). An industry perspective on health economics studies. The American Heart Journal, 137(5), S129–S132.

Antman, E. M., Giugliano, R. P., Gibson, C. M., McCabe, C. H., Coussement, P., Kleiman, N. S., Vahanian, A., Adgey, A. J., Menown, I., Rupprecht, H.-J., et al. (1999). Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation, 99(21), 2720–2732. https://doi.org/10.1161/01.cir.99.21.2720

Cabot, C., Anderson, K., Tcheng, J., & Lincoff, A. (1999). Abciximab reduces procedure time among patients undergoing percutaneous coronary intervention. American Journal of Cardiology, 84, 71P–71P.

Coussement, P., Antman, E., Giugliano, R., McCabe, C., Schuhwerk, K., Gibson, C., Scherer, J., Anderson, K., Braunwald, E., & Van de Werf, F. (1999). Comparison of two different thrombolytic regimens with and without abciximab in ST-elevation myocardial infarction: Observations from the TIMI 14 trial. Circulation, 100, 650–650.

Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J., Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C., Cabot, C. F., et al. (1999). Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Circulation, 99(15), 1951–1958. https://doi.org/10.1161/01.cir.99.15.1951

Mauskopf, J., Bala, M., Hermiller, J., Barber, B., & Anderson, K. (1999). TPCT2: Cost-effectiveness of abciximab in percutaneous coronary intervention patients: Results from a meta-analysis. Value in Health, 3(2), 153. https://doi.org/10.1016/S1098-3015(11)70886-5

Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J., Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C. F., et al. (1999). Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. The Lancet, 354(9195), 2019–2024. https://doi.org/10.1016/s0140-6736(99)10018-7

Antman, E., Giugliano, R., McCabe, C., Gibson, C., Adgey, A., Ghali, M., Coussement, P., Anderson, K., Scherer, J., Van de Werf, F., et al. (1998). Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 trial. Journal of the American College of Cardiology, 31(2SA), 191A–191A.

Gibson, C., Giugliano, R., Anderson, K., Scherer, J., McCabe, C., & Antman, E. (1998). Abciximab enhances thrombolysis: A comparison of abciximab alone versus abciximab plus low dose thrombolytics using the corrected TIMI frame count. Circulation, 98, 559–560.

Kereiakes, D., Lincoff, A., Simoons, M., deBoer, M., Tcheng, J., Vahanian, A., Anderson, K., Cabot, C., & Califf, R. (1998). Abciximab benefit in coronary intervention has no gender bias: Results of EPIC, EPILOG and CAPTURE trials. American Journal of Cardiology, 82, 95S–95S.

Kereiakes, D. J., Lincoff, A. M., Miller, D. P., Tcheng, J. E., Cabot, C. F., Anderson, K. M., Weisman, H. F., Califf, R. M., & Topol, E. J. (1998). Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications. Circulation, 97(9), 857–864. https://doi.org/10.1161/01.cir.97.9.857

Kereiakes, D., Berkowitz, S., Anderson, K., Simoons, M., Vahanian, A., Lincoff, A., Tcheng, J., Weisman, H., Califf, R., & Topol, E. (1998). Abciximab associated thrombocytopenia: Evidence for a complex interaction with heparin. Journal of the American College of Cardiology, 31, 55–55.

Kleiman, N. S., Lincoff, A. M., Kereiakes, D. J., Miller, D. P., Aguirre, F. V., Anderson, K. M., Weisman, H. F., Califf, R. M., & Topol, E. J. (1998). Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial. Circulation, 97(19), 1912–1920. https://doi.org/10.1161/01.cir.97.19.1912

Koreiakos, D., Lincoff, A., Simoons, M., deBoer, M., Tcheng, J., Vahanian, A., Anderson, K., Weisman, H., Califf, R., & Topol, E. (1998). Complementarity of stenting and abciximab for percutaneous coronary intervention. Journal of the American College of Cardiology, 31, 54–54.

Aguirre, F., Simoons, M., Ferguson, J., FitzPatrick, S., Anderson, K., Kern, M., & Tcheng, J. (1997). Impact of contrast media on clinical outcomes following percutaneous coronary interventions with platelet glycoprotein IIb/IIIa inhibition: Meta-analysis of clinical trials with abciximab. Circulation, 96, 898–898.

Blankenship, J., Anderson, K., Demko, S., Cabot, C., Kereiakes, D., & Aguirre, F. (1997). Decreased vascular access site bleeding after coronary intervention with abciximab in the EPILOG vs the EPIC trial. Circulation, 96, 896–896.

Blankenship, J., Anderson, K., Demko, S., Lincoff, A., Tcheng, J., & Cabot, C. (1997). In-lab angiographic complications during coronary intervention with abciximab vs placebo in the EPILOG trial. Circulation, 96, 905–905.

The CAPTURE Investigators. (1997). Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. The Lancet, 349(9063), 1429–1435. https://doi.org/10.1016/S0140-6736(96)10452-9

The EPILOG Investigators. (1997). Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New England Journal of Medicine, 336(24), 1689–1697. https://doi.org/10.1056/NEJM199706123362401

Gold, H., Kereiakes, D., Dinsmore, R., Martin, L., Lausten, D., Broderick, T., Anderson, K., Garabedian, H., & Leinbach, R. (1997). A randomized, placebo-controlled crossover trial of ReoPro alone or combined with low-dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: Preliminary results. Circulation, 96, 2649–2649.

Lincoff, A., Tcheng, J., Califf, R., Cabot, C., Miller, D., Booth, J., Montague, E., Anderson, K., & Topol, E. (1997). Abciximab (c7E3 Fab, ReoPro) with reduced heparin dosing during coronary intervention: Final results of the EPILOG trial. Journal of the American College of Cardiology, 29, 7396–7396.

Lincoff, A., Tcheng, J., Anderson, K., & Cabot, C. (1997). Durable inhibition of ischemic complications by abciximab during percutaneous coronary revascularization: One-year results of the EPILOG trial. Circulation, 96, 902–902.

Lincoff, A., Mark, D., Califf, R., Tcheng, J., Ellis, S., Davidson-Ray, L., Anderson, K., Stoner, G., & Topol, E. (1997). Economic assessment of platelet glycoprotein IIb/IIa receptor blockade during coronary intervention in the EPILOG trial. Journal of the American College of Cardiology, 29, 97484–97484.

Lincoff, A. M., Califf, R. M., Anderson, K. M., Weisman, H. F., Aguirre, F. V., Kleiman, N. S., Harrington, R. A., Topol, E. J., & investigators, E. (1997). Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. Journal of the American College of Cardiology, 30(1), 149–156. https://doi.org/10.1016/s0735-1097(97)00110-1

Lincoff, A. M., Tcheng, J. E., Califf, R. M., Bass, T., Popma, J. J., Teirstein, P. S., Kleiman, N. S., Hattel, L. J., Anderson, H. V., Ferguson, J. J., et al. (1997). Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. The American Journal of Cardiology, 79(3), 286–291. https://doi.org/10.1016/s0002-9149(96)00749-7

Mak, K.-H., Challapalli, R., Eisenberg, M. J., Anderson, K. M., Califf, R. M., Topol, E. J., investigators, E., et al. (1997). Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. The American Journal of Cardiology, 80(8), 985–988. https://doi.org/10.1016/s0002-9149(97)00589-4

Simoons, M., Harrington, R., Anderson, K., Deckers, J., & VanPapendrecht, M. (1997). Small, non-Q wave myocardial infarctions during PTCA, are associated with increased 6 months mortality. Circulation, 96, 163–163.

Tardiff, B., Anderson, K., Cabot, C., Deckers, J., & Simoons, M. (1997). Reduced need for coronary bypass surgery (CABG) after percutaneous intervention in patients treated with abciximab. Circulation, 96, 931–931.

Tcheng, J., Anderson, K., Tardiff, B., Cabot, C., Lincoff, A., Califf, R., & Topol, E. (1997). Reducing the risk of percutaneous intervention after coronary bypass surgery: Beneficial effects of abciximab treatment. Journals of the American College of Cardiology, 29, 7395–7395.

Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P., Anderson, K. M., et al. (1997). Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA, 278(6), 479–484. https://doi.org/10.1001/jama.1997.03550060055036

Aguirre, F. V., Topol, E. J., Anderson, K. M., Kleiman, N. S., Weisman, H. F., FitzPatrick, S. E., & Califf, R. M. (1996). Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial. The Journal of Invasive Cardiology, 8, 21B–29B.

Coller, B. S., Anderson, K. M., & Weisman, H. F. (1996). The anti-GPIIb-IIIa agents: Fundamental and clinical aspects. Pathophysiology of Haemostasis and Thrombosis, 26(Suppl. 4), 285–293. https://doi.org/10.1159/000217309

Lefkovits, J., Ivanhoe, R. J., Califf, R. M., Bergelson, B. A., Anderson, K. M., Stoner, G. L., Weisman, H. F., Topol, E. J., Investigators, G. E., et al. (1996). Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. The American Journal of Cardiology, 77(12), 1045–1051. https://doi.org/10.1016/s0002-9149(96)00128-2

Mark, D. B., Talley, J. D., Topol, E. J., Bowman, L., Lam, L. C., Anderson, K. M., Jollis, J. G., Cleman, M. W., Lee, K. L., Aversano, T., et al. (1996). Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation, 94(4), 629–635. https://doi.org/10.1161/01.cir.94.4.629

Aguirre, F. V., Topol, E. J., Ferguson, J. J., Anderson, K., Blankenship, J. C., Heuser, R. R., Sigmon, K., Taylor, M., Gottlieb, R., Hanovich, G., et al. (1995). Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation, 91(12), 2882–2890. https://doi.org/10.1161/01.cir.91.12.2882

Coller, B. S., Anderson, K., & Weisman, H. F. (1995). New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thrombosis and Haemostasis, 74(07), 302–308. https://doi.org/10.1055/s-0038-1642694

Lauer, M. S., Okin, P. M., Larson, M. G., Evans, J. C., Anderson, K. M., & Levy, D. (1995). Impaired heart rate response to graded exercise: Prognostic implications of chronotropic incompetence. Journal of the American College of Cardiology, 25(2), 171A.

Lauer, M. S., Okin, P. M., Anderson, K. M., & Levy, D. (1995). Impact of echocardiographic left ventricular mass on mechanistic implications of exercise testing parameters. The American Journal of Cardiology, 76(12), 952–956. https://doi.org/10.1016/s0002-9149(99)80268-9

Lefkovits, J., Anderson, K., Weisman, H., Topol, E. J., Investigators, E., et al. (1995). 711-5 mechanism of benefit of platelet IIb/IIIa receptor inhibition in high risk angioplasty in the EPIC trial: A hierarchical endpoint analysis. Journal of the American College of Cardiology, 25(2), 81A.

Lefkovits, J., Stoner, G., Anderson, K., Weisman, H., & Topol, E. (1995). Can conjunctive platelet glycoprotein IIb/IIIa receptor blockade improve outcomes of coronary interventions for restenotic lesions. Circulation, 92, 2907–2907.

Moliterno, D. J., Califf, R. M., Anderson, K., Weisman, H. F., & Topol, E. J. (1995). 935-34 special considerations for diabetics receiving platelet IIb/IIIa antagonists during coronary interventions: Results from the EPIC trialart. Journal of the American College of Cardiology, 25(2), 155A–156A.

Moliterno, D. J., Califf, R. M., Aguirre, F. V., Anderson, K., Sigmon, K. N., Weisman, H. F., Topol, E. J., EPIC Study Investigators, et al. (1995). Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). The American Journal of Cardiology, 75(8), 559–562. https://doi.org/10.1016/s0002-9149(99)80616-x

Weisman, H., Schaible, T., Jordan, R., Cabot, C., & Anderson, K. (1995). Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: Experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Biochemical Society Transactions, 23(4), 1051–1057. https://doi.org/10.1042/bst0231051

Cole, B. F., Gelber, R. D., & Anderson, K. M. (1994). Parametric approaches to quality-adjusted survival analysis. Biometrics, 621–631. https://doi.org/10.2307/2532777

Craen, A. J. de, Weverling, G. J., Anderson, K., & Tijssen, J. G. (1994). Patient randomization and medication distribution independent of the pharmaceutical sponsor. Controlled Clinical Trials, 15(3), 85–86. https://doi.org/10.1016/0197-2456(94)90143-0

The EPIC Investigators. (1994). Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New England Journal of Medicine, 330(14), 956–961. https://doi.org/10.1056/NEJM199404073301402

Lauer, M. S., Anderson, K. M., Larson, M. G., & Levy, D. (1994). A new method for indexing left ventricular mass for differences in body size. The American Journal of Cardiology, 74(5), 487–491. https://doi.org/10.1016/0002-9149(94)90909-1

Lefkovits, J., Anderson, K., Weisman, H., & Topol, E. (1994). Increased risk of non-Q MI following DCA: Evidence for a platelet dependent mechanism from the EPIC trial. Circulation, 90, 214–214.

Lefkovits, J., Ivanhoe, R., Anderson, K., Weisman, H., & Topol, E. (1994). Platelet-IIb/IIIa receptor inhibition during PTCA for acute myocardial-infarction—insights from the EPIC trial. Circulation, 90, 564–564.

Moliterno, D., Califf, R., Anderson, K., Sigmon, K., Aguirre, F., Weisman, H., & Topol, E. (1994). Activated clotting time is increased during coronary interventions with platelet IIb/IIIa antagonism-results from the EPIC trial. Journal of the American College of Cardiology, A106–A106.

Odell, P. M., Anderson, K. M., & Kannel, W. B. (1994). New models for predicting cardiovascular events. Journal of Clinical Epidemiology, 47(6), 583–592. https://doi.org/10.1016/0895-4356(94)90206-2

Topol, E., Califf, R., Weisman, H., Anderson, K., Wang, A., & Willerson, J. (1994). 6-month follow-up after acute-phase platelet IIb/IIIa integrin blockade in the EPIC trial-reduction in need for revascularization procedures. Journal of the American College of Cardiology, A60–A60.

Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley, S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994). Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six months. The Lancet, 343(8902), 881–886. https://doi.org/10.1016/S0140-6736(94)90007-8

Wilson, P. W., Anderson, K. M., Harri, T., Kannel, W. B., & Castelli, W. P. (1994). Determinants of change in total cholesterol and HDL-C with age: The Framingham Study. Journal of Gerontology, 49(6), M252–M257.

Anderson, K., Tannenbaum, M., Sanz, M., Wang, A., & Weisman, H. (1993). Clinical events following initially successful PTCA are platelet-mediated—results from the EPIC trial. Circulation, 88, 506–506.

Anderson, K. M., Wittes, J., Lee, K. L., Sigmon, K. N., & Weisman, H. F. (1993). Considerations for a group sequential, dose-response trial design. Controlled Clinical Trials, 14(5), 454. https://doi.org/10.1016/0197-2456(93)90197-L

Ellis, S. G., Tcheng, J. E., Navetta, F. I., Muller, D., Weisman, H. F., Smith, C., Anderson, K. M., Califf, R. M., & Topol, E. J. (1993). Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coronary Artery Disease, 4(2), 167–175. https://doi.org/10.1097/00019501-199302000-00007

Ho, K., Anderson, K. M., Kannel, W. B., Grossman, W., & Levy, D. (1993). Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation, 88(1), 107–115. https://doi.org/10.1161/01.CIR.88.1.107

Sutton, J., & Anderson, K. (1993). Body-weight and heparin dosing influence bleeding complications with c7E3 antiplatelet antibody. Circulation, 88, 209–209.

Tcheng, J., Topol, E., Kleiman, N., Ellis, S., Navetta, F., Fintel, D., Weisman, H., Anderson, K., Wang, A., Miller, J., et al. (1993). Improvement in clinical outcomes of coronary angioplasty by treatment with the GPIIb/IIIa inhibitor chimeric-7e3-multivariable analysis of the EPIC study. Circulation, 88, 506–506.

Anderson, K. M., & Kannel, W. B. (1992). Obesity and disease. In P. Björntorp & B. Brodoff (Eds.), Obesity (pp. 465–473). JB Lippincott Company. https://www.worldcat.org/isbn/9780397509997

Benjamin, E. J., Levy, D., Anderson, K. M., Wolf, P. A., Plehn, J. F., Evans, J. C., Comai, K., Fuller, D. L., & Sutton, M. S. J. (1992). Determinants of doppler indexes of left ventricular diastolic function in normal subjects (the Framingham Heart Study). The American Journal of Cardiology, 70(4), 508–515. https://doi.org/10.1016/0002-9149(92)91199-e

Berger, C. J., Murabito, J. M., Evans, J. C., Anderson, K. M., & Levy, D. (1992). Prognosis after first myocardial infarction: Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA, 268(12), 1545–1551. https://doi.org/10.1001/jama.1992.03490120059029

Castelli, W. P., Anderson, K., Wilson, P. W., & Levy, D. (1992). Lipids and risk of coronary heart disease The Framingham Study. Annals of Epidemiology, 2(1-2), 23–28. https://doi.org/10.1016/1047-2797(92)90033-m

Genest Jr, J., McNamara, J. R., Ordovas, J. M., Jenner, J. L., Silberman, S. R., Anderson, K. M., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992). Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. Journal of the American College of Cardiology, 19(4), 792–802. https://doi.org/10.1016/0735-1097(92)90520-w

Kannel, W., Anderson, K., & Evans, J. (1992). Relevance of blood lipids in the elderly: The Framingham Study. Cardiovasc Risk Factors, 2, 170–179.

Kannel, W. B., Anderson, K., & Wilson, P. W. (1992). White blood cell count and cardiovascular disease: Insights from the Framingham Study. JAMA, 267(9), 1253–1256. https://doi.org/10.1001/jama.1992.03480090101035

Kreger, B. E., Anderson, K. M., Schatzkin, A., & Splansky, G. L. (1992). Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer, 70(5), 1038–1043. https://doi.org/10.1002/1097-0142(19920901)70:5<1038::aid-cncr2820700505>3.0.co;2-m

Lauer, M. S., Anderson, K. M., & Levy, D. (1992). Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: The Framingham Heart Study. Journal of the American College of Cardiology, 19(1), 130–134. https://doi.org/10.1016/0735-1097(92)90063-s

Lauer, M. S., Levy, D., Anderson, K. M., & Plehn, J. F. (1992). Is there a relationship between exercise systolic blood pressure response and left ventricular mass? The Framingham Heart Study. Annals of Internal Medicine, 116(3), 203–210. https://doi.org/10.7326/0003-4819-116-3-203

Levy, D., Murabito, J. M., Anderson, K. M., Christiansen, J. C., & Castelli, W. P. (1992). Echocardiographic left ventricular hypertrophy: Clinical characteristics. The Framingham Heart Study. Clinical and Experimental Hypertension. Part A: Theory and Practice, 14(1-2), 85–97. https://doi.org/10.3109/10641969209036173

O’Leary, D. H., Anderson, K. M., Wolf, P. A., Evans, J. C., & Poehlman, H. W. (1992). Cholesterol and carotid atherosclerosis in older persons: The Framingham Study. Annals of Epidemiology, 2(1-2), 147–153. https://doi.org/10.1016/1047-2797(92)90049-v

Odell, P. M., Anderson, K. M., & D’Agostino, R. B. (1992). Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics, 951–959. https://doi.org/10.2307/2532360

Singer, D. E., Nathan, D. M., Anderson, K. M., Wilson, P. W., & Evans, J. C. (1992). Association of HbA_1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes, 41(2), 202–208. https://doi.org/10.2337/diab.41.2.202

Anderson, K. M., Odell, P. M., Wilson, P. W., & Kannel, W. B. (1991). Cardiovascular disease risk profiles. American Heart Journal, 121(1), 293–298. https://doi.org/10.1016/0002-8703(91)90861-b

Anderson, K. M., Dumphy, D. C., & Wilson, P. W. F. (1991). Management of data quality in a long-term epidemiologic study: The Framingham Heart Study. In Data quality control theory and pragmatics (pp. 57–68). Marcel Dekker, Inc.

Anderson, K. M. (1991). A nonproportional hazards Weibull accelerated failure time regression model. Biometrics, 281–288. https://doi.org/10.2307/2532512

Anderson, K. M., Wilson, P., Odell, P. M., & Kannel, W. B. (1991). An updated coronary risk profile: A statement for health professionals. Circulation, 83(1), 356–362. https://doi.org/10.1161/01.CIR.83.1.356

Benjamin, E. J., Anderson, K. M., Plehn, J. F., Comai, K., Fuller, D., Evans, J. C., Wolf, P. A., Sutton, M. S. J., & Levy, D. (1991). The impact of age on left ventricular diastolic function in healthy subjects from the Framingham Heart Study. Journal of the American College of Cardiology, 17(2S1), A329–A329.

Galderisi, M., Anderson, K. M., Wilson, P. W., & Levy, D. (1991). Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). The American Journal of Cardiology, 68(1), 85–89. https://doi.org/10.1016/0002-9149(91)90716-x

Goldberg, R. J., Bengtson, J., Chen, Z., Anderson, K. M., Locati, E., & Levy, D. (1991). Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). The American Journal of Cardiology, 67(1), 55–58. https://doi.org/10.1016/0002-9149(91)90099-7

Kreger, B. E., Anderson, K. M., & Levy, D. (1991). QRS interval fails to predict coronary disease incidence: The Framingham Study. Archives of Internal Medicine, 151(7), 1365–1368. https://doi.org/10.1001/archinte.1991.00400070127016

Lauer, M. S., Anderson, K. M., Kannel, W. B., & Levy, D. (1991). The impact of obesity on left ventricular mass and geometry: The Framingham Heart Study. JAMA, 266(2), 231–236. https://doi.org/10.1001/jama.1991.03470020057032

Lauer, M., Anderson, K., & Levy, D. (1991). The impact of long-term blood-pressure on left-ventricular mass and geometry. Hypertension, 18, 426–426.

Lauer, M. S., Anderson, K. M., & Levy, D. (1991). Influence of contemporary versus 30-year blood pressure levels on left ventricular mass and geometry: The Framingham Heart Study. Journal of the American College of Cardiology, 18(5), 1287–1294. https://doi.org/10.1016/0735-1097(91)90549-o

Okin, P. M., Anderson, K., Levy, D., & Kligfield, P. (1991). Heart rate adjustment of exercise-induced ST segment depression. Improved risk stratification in the Framingham Offspring Study. Circulation, 83(3), 866–874. https://doi.org/10.1161/01.cir.83.3.866

Wilson, P. W., Anderson, K. M., & Castelli, W. (1991). The impact of triglycerides on coronary heart disease: The Framingham Study. Athero Rev, 22, 59–63.

Wilson, P. W., Anderson, K. M., Castelli, W. P., & Kannel, W. B. (1991). Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: The Framingham Offspring Study. The American Journal of Medicine, 90(1), 11–16. https://doi.org/10.1016/0002-9343(91)90500-w

Anderson, K. (1990). Coffee, lipids and cardiovascular disease. The Framingham Offspring Study. Workshop on Coffee and Coronary Heart Disease with Special Emphasis on the Coffee-Blood Lipids Relationship: Proceedings: Three Main Areas, Blood Lipids, Cross-Sectional Studies Experiments, Coffee and Chd, Physiological Mechanisms, 127.

Ballard-Barbash, R., Schatzkin, A., Carter, C. L., Kannel, W. B., Kreger, B. E., D’Agostino, R. B., Splansky, G. L., Anderson, K. M., & Helsel, W. E. (1990). Body fat distribution and breast cancer in the Framingham Study. JNCI: Journal of the National Cancer Institute, 82(4), 286–290. https://doi.org/10.1093/jnci/82.4.286

Ballard-Barbash, R., Schatzkin, A., Albanes, D., Schiffman, M. H., Kreger, B. E., Kannel, W. B., Anderson, K. M., & Helsel, W. E. (1990). Physical activity and risk of large bowel cancer in the Framingham Study. Cancer Research, 50(12), 3610–3613. https://aacrjournals.org/cancerres/article/50/12/3610/495240/

D’Agostino, R. B., Lee, M.-L., Belanger, A. J., Cupples, L. A., Anderson, K., & Kannel, W. B. (1990). Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Statistics in Medicine, 9(12), 1501–1515. https://doi.org/10.1002/sim.4780091214

Jones, M. G., Anderson, K. M., Wilson, P. W., Kannel, W. B., Wagner, N. B., & Wagner, G. S. (1990). Prognostic use of a QRS scoring system after hospital discharge for initial acute myocardial infarction in the Framingham cohort. The American Journal of Cardiology, 66(5), 546–550. https://doi.org/10.1016/0002-9149(90)90479-k

Kannel, W., Anderson, K., & Zhang, T. (1990). White blood-count and cardiovascular disease—insights from the Framingham study. Circulation, 82, 119–119.

Kaufman, H. W., McNamara, J. R., Schaefer, E. J., Anderson, K. M., & Wilson, P. W. F. (1990). Portable cholesterol analyzers-reply. JAMA, 264(9), 1102–1103. https://doi.org/10.1001/jama.1990.03450090037015

Kaufman, H. W., McNamara, J. R., Anderson, K. M., Wilson, P. W., & Schaefer, E. J. (1990). How reliably can compact chemistry analyzers measure lipids? JAMA, 263(9), 1245–1249. https://doi.org/10.1001/jama.1990.03440090079031

Levy, D., Labib, S. B., Anderson, K. M., Christiansen, J. C., Kannel, W. B., & Castelli, W. P. (1990). Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation, 81(3), 815–820. https://doi.org/10.1161/01.cir.81.3.815

Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New England Journal of Medicine, 322(22), 1561–1566. https://doi.org/10.1056/NEJM199005313222203

Levy, D., Wilson, P. W., Anderson, K. M., & Castelli, W. P. (1990). Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. American Heart Journal, 119(3), 712–717. https://doi.org/10.1016/s0002-8703(05)80050-x

Murabito, J. M., Anderson, K. M., Kannel, W. B., Evans, J. C., & Levy, D. (1990). Risk of coronary heart disease in subjects with chest discomfort: The Framingham Heart Study. The American Journal of Medicine, 89(3), 297–302. https://doi.org/10.1016/0002-9343(90)90341-a

Okin, P. M., Anderson, K. M., Lavy, D., & Kligfield, P. (1990). Improved risk in prediction in the Framingham offspring study by heart rate adjustment of ST segment depression. Journal of the American College of Cardiology, 15(2SA), A81–A81.

O’Leary, D., Anderson, K., Kase, C., Evans, J., Poehlman, H., & Wolf, P. (1990). Extracranial carotid atherosclerosis in an elderly population—the Framingham study. Circulation, 81, 724–724.

Singer, D., Nathan, D., Wilson, P., & Anderson, K. (1990). Hemoglobin A1C as a risk factor for cardiovascular-disease in the Framingham study. Clinical Research, 38, A228–A228.

Wilson, P., Kannel, W., Anderson, K., & Castelli, W. (1990). Cholesterol and CHD in the elderly—the Framingham cohort. Circulation, 82, 576–576.

Wilson, P., & Anderson, K. (1990). HDL cholesterol and triglycerides as risk factors for CHD. In Atherosclerosis and cardiovascular disease (pp. 609–615). Springer. https://doi.org/10.1007/978-94-009-0731-7_78

Ballard-Barbash, R., Schatzkin, A., Carter, C., Kannel, W., Kreger, B., Splansky, G., Anderson, K., & Helsel, W. (1989). Body-fat distribution and breast-cancer in the Framingham Heart Study. American Journal of Epidemiology, 130, 852–853.

Castelli, W. P., Wilson, P. W., Levy, D., & Anderson, K. (1989). Cardiovascular risk factors in the elderly. The American Journal of Cardiology, 63(16), 12–19. https://doi.org/10.1016/0002-9149(89)90110-0

Hodges, D., Cook, E., Anderson, K., Kannel, W., & Goldman, L. (1989). Alcohol and the risk of congestive heart failure—the Framingham Heart Study. Clinical Research, 37, A313–A313.

Kreger, B. E., Anderson, K. M., & Kannel, W. B. (1989). Prevalence of intraventricular block in the general population: The Framingham Study. American Heart Journal, 117(4), 903–910. https://doi.org/10.1016/0002-8703(89)90630-3

Preisler, H., Anderson, K., Rai, K., Cuttner, J., Yates, J., DuPre, E., & Holland, J. (1989). The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: A study of 760 patients with a minimal follow-up time of 6 years. British Journal of Haematology, 71(2), 189–194. https://doi.org/10.1111/j.1365-2141.1989.tb04253.x

Schatzkin, A., Carter, C. L., Green, S. B., Kreger, B. E., Splansky, G. L., Anderson, K. M., Helsel, W. E., & Kannel, W. B. (1989). Is alcohol consumption related to breast cancer? Results from the Framingham Heart Study. JNCI: Journal of the National Cancer Institute, 81(1), 31–35. https://doi.org/10.1093/jnci/81.1.31

Wilson, P. W., Christiansen, J. C., Anderson, K. M., & Kannel, W. B. (1989). Impact of national guidelines for cholesterol risk factor screening: The Framingham Offspring Study. JAMA, 262(1), 41–44. https://doi.org/10.1001/jama.1989.03430010053030

Wilson, P., & Anderson, K. (1989). Isolated hypoalphalipoproteinemia and premature heart-disease—the Framingham Offspring Study. Arteriosclerosis, 9, A708–A708.

Wilson, P. W. F., Anderson, K. M., & Christiansen, J. C. (1989). Putting cholesterol control on a diet-reply. JAMA, 262(21), 2998–2998. https://doi.org/10.1001/jama.1989.03430210036019

Discussion. Risk factors and survival. (1988). Statistics in Medicine, 7(1-2), 297–302. https://doi.org/10.1002/sim.4780070130

Cupples, L. A., D’Agostino, R. B., Anderson, K., & Kannel, W. B. (1988). Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Statistics in Medicine, 7(1-2), 205–218. https://doi.org/10.1002/sim.4780070122

Hands, M. E., Sia, S. B., Shook, T. L., Anderson, K., Stone, P. H., Levy, D., Castelli, W. P., Rutherford, J. D., Group, F. H. S., et al. (1988). Silent myocardial ischemia in asymptomatic survivors of unrecognized myocardial infarction and matched controls. American Heart Journal, 116(6), 1488–1492. https://doi.org/10.1016/0002-8703(88)90733-8

Levy, D., Anderson, K. M., Christiansen, J. C., Campanile, G., & Stokes III, J. (1988). Antihypertensive drug therapy and arrhythmia risk. The American Journal of Cardiology, 62(1), 147–149. https://doi.org/10.1016/0002-9149(88)91383-5

Levy, D., Anderson, K. M., Savage, D. D., Kannel, W. B., Christiansen, J. C., & Castelli, W. P. (1988). Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors: The Framingham Heart Study. Annals of Internal Medicine, 108(1), 7–13. https://doi.org/10.7326/0003-4819-108-1-7

O’Leary, D., Anderson, K., Kase, C., Wolf, P., & Kannel, W. (1988). Extracranial carotid atherosclerosis in a general population—the Framingham Study. Stroke, 19, 143–143.

Singer, D., Nathan, D., Wilson, P., & Anderson, K. (1988). Glycated hemoglobin is associated with cardiovascular-disease in females of the Framingham cohort, even among non-diabetics. Clinical Research, 36, A350–A350.

Anderson, K. M., Castelli, W. P., & Levy, D. (1987). Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA, 257(16), 2176–2180. https://doi.org/10.1001/jama.1987.03390160062027

Anderson, K. M. (1987). Cholesterol and mortality-reply. JAMA, 258(12), 1609–1609. https://doi.org/10.1001/jama.1987.03400120058023

Anderson, K. M., Wilson, P. W., Garrison, R. J., & Castelli, W. P. (1987). Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample The Framingham Offspring Study. Atherosclerosis, 68(1-2), 59–66. https://doi.org/10.1016/0021-9150(87)90094-3

Kannel, W. B., Anderson, K., McGee, D. L., Degatano, L. S., & Stampfer, M. J. (1987). Nonspecific electrocardiographic abnormality as a predictor of coronary heart disease: The Framingham Study. American Heart Journal, 113(2), 370–376. https://doi.org/10.1016/0002-8703(87)90280-8

Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel, W. B., & Castelli, W. P. (1987). Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. The American Journal of Cardiology, 59(9), 956–960. https://doi.org/10.1016/0002-9149(87)91133-7

Levy, D., Anderson, K. M., Plehn, J., Savage, D. D., Christiansen, J. C., & Castelli, W. P. (1987). Echocardiographically determined left ventricular structural and functional correlates of complex or frequent ventricular arrhythmias on one-hour ambulatory electrocardiographic monitoring. The American Journal of Cardiology, 59(8), 836–840. https://doi.org/10.1016/0002-9149(87)91102-7

Levy, D., Anderson, K., Savage, D., Kannel, W., & Castelli, W. (1987). Influence of 30 year mean blood-pressure levels on left-ventricular mass—the Framingham Heart Study. Journal of the American College of Cardiology, 9, A115–A115.

Levy, D., Anderson, K. M., Savage, D. D., Balkus, S. A., Kannel, W. B., & Castelli, W. P. (1987). Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. The American Journal of Cardiology, 60(7), 560–565. https://doi.org/10.1016/0002-9149(87)90305-5

O’Connor, G., Anderson, K., Kannel, W., Brand, F., Christiansen, J., Weiss, S., & Speizer, F. (1987). Prevalence and prognosis of dyspnea in the Framingham Study. Chest, 92(Suppl 2), 90S.

Plehn, J., Levy, D., Anderson, K., Savage, D., & Stokes, J. (1987). Failure of exercise blood-pressure parameters to predict left-ventricular mass—the Framingham Heart Study. Journal of the American College of Cardiology, 9, A51–A51.

Anderson, K., Castelli, W., & Stokes, J. (1986). Repeated measures of body-mass index and mortality—the Framingham study. American Journal of Epidemiology, 124, 514–514.

Castelli, W. P., & Anderson, K. (1986). A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. The American Journal of Medicine, 80(2), 23–32. https://doi.org/10.1016/0002-9343(86)90157-9

Levy, D., Anderson, K., Christiansen, J., & Stokes, J. (1986). Prevalence of ventricular arrhythmias in hypertensives treated with β-blockers or diuretics—the Framingham Heart Study. Circulation, 74, 489–489.

Olson, W., Bennett, T., Huberty, K., & Anderson, K. (1986). Automatic detection of ventricular-fibrillation with chronically implanted pressure sensors. Journal of the American College of Cardiology, 7, A182–A182.

Sharma, A., Sutton, R., Bennett, T., Klein, G., Anderson, K., & Beck, R. (1986). Physiological pacing based on beat-to-beat measurement of right ventricular dP/dt_max—initial feasibility studies in man. Journal of the American College of Cardiology, 7, A3–A3.

Sobol, R. E., Mick, R., Lebien, T. W., Ozer, H., Minowada, J., Anderson, K., Ellison, R. R., Cuttner, J., Morrison, A., Richards II, F., et al. (1986). The reproducibility of acute lymphoblastic leukemia phenotype determinations: Evaluation of monoclonal antibody and conventional hematopoietic markers. Leukemia Research, 10(5), 481–485. https://doi.org/10.1016/0145-2126(86)90083-4

Wilson, P. W., Anderson, K. M., & Kannel, W. B. (1986). Epidemiology of diabetes mellitus in the elderly: The Framingham Study. The American Journal of Medicine, 80(5), 3–9. https://doi.org/10.1016/0002-9343(86)90532-2

Bennett, T., Baudino, M., Bornzin, G., Anderson, K., & Olson, W. (1985). Rate-responsive pacing using dynamic right ventricular pressure in heart-blocked dogs. Journal of the American College of Cardiology, 5, 393–393.

Goetzler, R., Stokes III, J., & Anderson, K. (1985). Prognosis of subjects in the Framingham Study with rheumatic heart disease. Journal of the American Geriatrics Society, 33(10), 693–697. https://doi.org/10.1111/j.1532-5415.1985.tb01778.x

Kreger, B., Provencher, L., Anderson, K., & Kannel, W. (1985). Prevalence of intraventricular block in the general population—the Framingham study. Journal of the American College of Cardiology, 5, 443–443.

Levy, D., Savage, D., Garrison, R., Balkus, S., Anderson, K., Kannel, W., & Castelli, W. (1985). The association of left-ventricular hypertrophy with ventricular arrhythmias—the Framingham Heart Study. Circulation, 72, 46–46.

Sobol, R., Royston, I., LeBien, T., Minowada, J., Anderson, K., Davey, F., Cuttner, J., Schiffer, C., Ellison, R., & Bloomfield, C. (1985). Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies. Blood, 65(3), 730–735. https://doi.org/10.1182/blood.V65.3.730.730

Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., & Lee, J. E. (1985). Early precursors of site-specific cancers in college men and women. JNCI: Journal of the National Cancer Institute, 74(1), 43–51. https://doi.org/10.1093/jnci/74.1.43

Wilson, P., Kannel, W., & Anderson, K. (1985). Lipids, glucose intolerance and vascular disease: The Framingham Study. Monographs on Atherosclerosis, 13, 1–11.

Anderson, K. (1983). Convergence of the moment generating function of standardized quantiles. Communications in Statistics-Theory and Methods, 12(21), 2445–2454. https://doi.org/10.1080/03610928308828611

Hauck, W. W., Whittemore, A. S., McLarty, J. W., Fortson, N., & Anderson, K. (1983). Regression analysis of cytopathological data-reply. Biometrics, 39(4), 1114–1114. http://www.jstor.org/stable/2531348

Whittemore, A. S., Paffenbarger Jr, R. S., Anderson, K., & Halpern, J. (1983). Early precursors of pancreatic cancer in college men. Journal of Chronic Diseases, 36(3), 251–256. https://doi.org/10.1016/0021-9681(83)90059-0

Anderson, K. M. (1982). Moment expansions for robust statistics. Stanford University. Department of Statistics. https://purl.stanford.edu/sn138ps6683

Anderson, K., Sobel, M., & Uppuluri, V. (1982). Quota fulfillment times. Canadian Journal of Statistics, 10(2), 73–88. https://doi.org/10.2307/3314900

Whittemore, A. S., McLarty, J. W., Fortson, N., & Anderson, K. (1982). Regression analysis of cytopathological data. Biometrics, 899–905. https://doi.org/10.2307/2529870

Anderson, K. (1980). Convergence of moments of standardized quantiles. Stanford University. Department of Statistics. https://purl.stanford.edu/dq501zc0680

Anderson, K., Sobel, M., & Uppuluri, V. (1980). Multivariate hypergeometric and multinomial waiting times. Stanford University. Department of Statistics. https://purl.stanford.edu/gt383hn1006